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Abstract Tumor-related activities that seem to be opera-
tionally induced by the division of function, such as
inflammation, neoangiogenesis, Warburg effect, immune
response, extracellular matrix remodeling, cell proliferation
rate, apoptosis, coagulation effects, present itself from a
systems perspective as an enhancement of complexity. We
hypothesized, that tumor systems-directed therapies might
have the capability to use aggregated action effects, as
adjustable sizes to therapeutically modulate the tumor
systems’ stability, homeostasis, and robustness. We per-
formed a retrospective analysis of recently published data
on 224 patients with advanced and heavily pre-treated (10%
to 63%) vascular sarcoma, melanoma, renal clear cell,
cholangiocellular, carcinoma, hormone-refractory prostate
cancer, and multivisceral Langerhans’ cell histiocytosis
enrolled in nine multi-center phase II trials (11 centers).
Each patient received a multi-targeted systems-directed
therapy that consisted of metronomic low-dose chemother-
apy, a COX-2 inhibitor, combined with one or two
transcription modulators, pioglitazone +/− dexamethasone
or IFN-alpha. These treatment schedules may attenuate the
metastatic potential, tumor-associated inflammation, may
exert site-specific activities, and induce long-term disease
stabilization followed by prolonged objective response (3%
to 48%) despite poor monoactivity of the respective drugs.
Progression-free survival data are comparable with those of
reductionist-designed standard first-line therapies. The
differential response patterns indicate the therapies’ systems
biological activity. Understanding systems biology as
adjustable size may break through the barrier of complex
tumor-stroma-interactions in a therapeutically relevant way:
Comparatively high efficacy at moderate toxicity. Struc-
tured systems-directed therapies in metastatic cancer may
get a source for detecting the topology of tumor-associated
complex aggregated action effects as adjustable sizes






Unlike laws of nature, causal relations between initiating
processes of tumor development are not anchored in an
invariance of nature. Therefore, molecular and cytogenetic
aberrations at initial diagnosis are generally heterogeneous
in both tumors and single tumor types. Invariance within
the tumor process may be observed during tumor progression.
In interaction with normal human tissue, tumor cells use
processes according to laws of nature to build up a favorable
infrastructureforproliferation.In1986,Dvorakinterpretedfor
the first time these laws of nature as tumor-associated ‘wound
healing’ mechanisms such as angiogenesis, inflammation,
immunology, remodeling of the extracellular matrix, specific
changes in cell metabolism and coagulation, and altered
behavior in proliferation [1–7]. Accordingly, tumors may be
figuratively conceived as ‘never healing wounds’. With this
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Department of Dermatology, University Hospital Regensburg,
Regensburg, Germanyinterpretation, Dvorak addressed the systems biology of a
tumor in a contemporary context. Up to now, a tumor’s
systems biology has rarely presented a target for a systematic
approach in cancer treatment.
The dysregulated systems biology of a tumor may
commonly not be understood mono-causally or explained
context-free. The tumor’s systems biology intents on a
dysbalance between interfering functional elements in a
way that conditioning and conditioned tumor-promoting
elements (e.g. wound healing mechanisms) behave recip-
rocally also under therapeutic aspects.
The dysregulation of wound healing mechanisms is
reflected in tumor-associated disease traits (e.g. tumor-
associated inflammation, ECOG performance status, throm-
bophilia, and tumor-associated auto-immunity) and on the
molecular level in the dysregulation of (nuclear) transcrip-
tion factors, both in tumor and neighboring stroma cells.
Transcription factors regulate in a concerted action distinct
gene cascades and consecutively important cell functions
for survival. Their cooperative interaction is also important
for the survival of tumor cells.
In seven published phase II trials, we combined modu-
lators (ligands) of (nuclear) transcription factors (pioglita-
zone, dexamethasone, interferon-alpha, cyclo-oxygenase-2
(COX-2) inhibitors) with the aim to suppress tumor-
associated inflammation [8–15]. Corticosteroids are known
for their anti-inflammatory activity; interferon-alpha at low
doses (3.0 to 4.5 MU three times a week) shows both anti-
inflammatory and angiostatic activity as well as the anti-
diabetic drug pioglitazone (peroxisome proliferator-activated
receptor (PPAR)-alpha/gamma agonist) [16–18]. Besides its
anti-inflammatory activity, the COX-2 inhibitor also exerts
an anti-proliferative via suppression of the PPAR-delta
expression [19]. The efficacy of the anti-inflammatory
therapy approach was controlled by the measurement of C-
reactive protein (CRP) levels in serum.
To enhance the therapeutic efficacy, a second wound
healing mechanism was therapeutically targeted: neoangio-
genesis. Metronomic low-dose chemotherapy with either
trofosfamide or capecitabine may enhance the important
antiangiogenic factor thrombospondin-1 in serum with
simultaneously negligible cytotoxic activity of the respec-
tive drugs [20]. The present therapeutic approach – a
combination of anti-inflammatory, angiostatic and immu-
nomodulatory therapy – is primarily directed against
invariant mechanisms embedded in the laws of nature that
are generally important during tumor progression. There-
fore, treatment efficacy may be expected to some degree,
independently of the tumor type.
The summary of recently published data on combined
anti-inflammatory and angiostatic therapy approaches in
metastatic cancer may support the ‘wound healing’ hypoth-
esis from a therapeutic view. Firstly, we want to show with
our data from seven clinical trials that different anti-
inflammatory approaches are not only clinically efficacious
and safe but show a moderate toxicity profile and may even
induce continuous complete remission in combination with
angiostatic therapies. Secondly, we are going to demon-
strate according to the observed typical response character-
istics that our therapeutic approaches have primarily
biomodulatory rather than classic cytotoxic activity. Third-
ly, we have introduced combined anti-inflammatory and
angiostatic approaches for the therapy of metastatic tumors.
The combined activity may even induce continuous
complete remission.
The summarized results of the presented biomodulatory
therapy approaches in different metastatic tumors contradict
the paradigm that for the most part only drug-mediated
blockades of more or less tumor-specific aberrant pathways
may induce tumor response, a paradigm which is supported
by an overwhelming number of clinical data.
Patients and Methods
Selection of Metastatic Diseases
We performed retrospective analyses of recently published
data from our study group on patients with advanced and
heavilypre-treatedtumors(Table1). According to our chosen
therapeutic approaches – a combined anti-inflammatory and
angiostatic therapy – we selected (1) tumors with high
vascular density such as vascular sarcomas and renal clear
cell carcinomas (RCCC), (2) a highly inflammatory tumor
type, i.e. chemo-resistant multivisceral Langerhans’ cell
histiocytosis, and (3) tumors with a known inflammatory
component at least in the metastatic stage (melanoma,
cholangiocellular carcinoma, and hormone-refractory pros-
tate cancer (HRPC). All patients were enrolled in phase II
trials, and melanoma patients additionally participated in a
randomized phase II trial.
Patients’ Characteristics
The local ethics committee approved study protocols, and
patients were required to provide written informed consent
before enrolment. Patients presented were recruited be-
tween February 2001 and July 2006 in seven phase II trials
including one randomized phase II trial in metastatic
melanoma. Patients with advanced bidimensionally mea-
surable neoplasias, either systemically pretreated or not,
who experienced disease progression and who had a life
expectancy of more than three months were eligible for the
studies. Controlled brain metastases were no exclusion
criteria. The remaining inclusion criteria are indicated in the
respective publication.
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Treatment schedules were intended to achieve disease
stabilization in metastatic neoplasias of different origin
with uniform biomodulatory treatment principles and to
limit therapy-related toxicity in advanced tumor stages. All
patients received a combined anti-inflammatory and angio-
static therapy consisting of (1) metronomic low-dose
chemotherapy (trofosfamide or capecitabine), (2) COX-2/
PPAR (peroxisome proliferator-activated receptor)-delta
blockade (rofecoxib or etoricoxib) combined with (3) one
or two transcription modulators, i.e. pioglitazone (peroxi-
some proliferator receptor alpha/gamma agonist) +/−
dexamethason or pioglitazone +/− IFN-alpha (Table 1)[ 8–15].
Anti-inflammatory Therapies
We have chosen drugs with transcriptional activity in the field
of inflammation control: glucocorticoids (dexamethasone 0.5
to 1.0 mg daily), interferon-alpha (3 to 4.5 MU three times a
week), and the glitazone pioglitazone (45 to 60 mg daily).
Also the administered coxibs (rofecoxib 12.5 to 25 mg daily
oretoricoxib60mgdaily)mayexpresstranscriptionalactivity
by the inhibition of PPAR-delta. The transcriptional modu-
lators used are all multifunctional modulators that may not
only achieve specification of their activity by nuclear receptor
cross-talk [21–23] but may also have important receptor
dependent (genomic and non-genomic) as well as indepen-
dent (non-genomic) activities [17, 18, 24].
Furthermore, anti-inflammatory approaches were selected
according to known effects of dexamethasone in hormone-
refractory prostate cancer and interferon-alpha (at high-doses)
in metastatic renal cell carcinoma. Interferon-alpha was used
at a dose level for angiostatic activity, i.e. at very low doses.
In metastatic RCCC, we selected in a second consecutive
trial an anti-inflammatory approach with presumably
enhanced anti-inflammatory capacity: pioglitazone, coxib,
and additionally interferon-alpha [12]. In HRPC, a combi-
nation of two activators of nuclear transcription factors
(pioglitazone and dexamethasone) has been introduced
[14].
A randomized phase II trial (metastatic melanoma)
evaluated the additional effects of anti-inflammatory ther-
apy in addition to metronomic low-dose chemotherapy on
progression-free and overall survival (combined anti-
inflammatory/angiostatic vs. angiostatic approach) [9].
In the trials melanoma I, sarcoma I, and vascular
sarcomas, we introduced a 14 day lead-in phase with anti-
inflammatory therapy only (pioglitazone plus rofecoxib or
etoricoxib) [8, 9].
Angiostatic Therapies
Angiostatic therapy consisted of metronomic low-dose
chemotherapy, either 50 mg oral trofosfamide (Baxter)
administered continuously 2 or 3 times daily or 1 g/m
2 to
1 g absolute oral capecitabine (Roche) administered twice
per day.















Kaposi sarcoma Trofosfamide 1 + + −− Arch Dermatol, 2004
Angiosarcomas Trofosfamide 6 + + −− Cancer, 2003
Sarcomas I Trofosfamide 21 + + −− Cancer, 2004
Melanoma I Trofosfamide 19 + + −− Cancer, 2004
Melanoma II Arm A 35 −−− − Melanoma Research, 2007
Arm B 32 + + −−
Langerhans’ cell histiocytosis Trofosfamide 2 + + −− Br. J.Haematol, 2005
Renal clear cell carcinoma I Capecitabine 18 + + −− Biomarker Insights, 2006
Renal clear cell
carinoma II
Capecitabine 33 + + − + Biomarker Insights, 2006
Hormone-refractory
prostate cancer




Capecitabine 21 + + −− Tumor Microenvironment
Prague, 2004 (Medimond)
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Patients were centrally randomized for the Melanoma II
trial. Arm A received 50 mg oral trofosfamide (Baxter)
administered continuously three times daily from day 1 +,
Arm B of trofosfamide in the same dosage plus continu-
ously 60 mg oral pioglitazone (Takeda) and 25 mg oral
rofecoxib (MSD) once daily starting with day 1 +.
Treatment was continued until disease progression was
documented or for a maximum of six weeks after
confirmation of CR. Following disease progression, a
crossover from Arm A to B was allowed.
Patients treated in the vascular sarcoma trial (including
one patient with Kaposi sarcoma), in the Melanoma I,
Sarcoma I, and Langerhans cell histiocytosis trials received
Arm B-therapy as described above. Melanoma and sarcoma
patients had a lead-in phase with anti-inflammatory therapy
alone over 14 days. Patients in the RCCC study I received
1 g/m
2 oral capecitabine (Roche) administered twice daily
from day 1+, 60 mg oral pioglitazone (Takeda). Patients
enrolled before November 2004 also received 25 mg oral
rofecoxib daily, whereas patients enrolled after November
2004 were given 60 mg oral etoricoxib daily instead,
starting with day 1+. Patients in study II (RCCC II)
received additionally 4.5 MU IFN-alpha subcutaneously,
three times per week, from day 1+. Patients with chol-
angiocellular carcinoma were treated with the schedule of
RCCC I.
Combined Targeting of Wound Healing Processes
In all studies, we selected transcriptional modulators including
those of nuclear transcription factors with the aim to control
tumor-associated inflammation. For metastatic melanoma, we
performed a randomized phase II trial to directly study the
impact of inflammation control on progression-free and overall
survival. A historic comparison (RCCC I/II) shows the impact
of weak versus strong control of tumor-associated inflamma-
tion on progression-free and overall survival in renal clear cell
carcinoma. In hormone-refractory prostate cancer, published
data from metronomic cyclophosphamide and dexamethasone
treatment are available for a historical comparison [25].
Pre-treatment Evaluation is Indicated in the Respective
Publications
Evaluation of Efficacy
Response and toxicity were evaluated in patients who had a
follow-up duration of ≥ three weeks. Objective tumor
responses were identified using the World Health Organi-
zation (WHO) criteria (vascular sarcomas, sarcomas,
melanomas) or RECIST criteria (RCCC and HRPC).
Modulation of Tumor-associated Disease Traits
ECOG status ECOG performance status was routinely
monitored.
Monitoring of CRP Serum CRP levels were measured in
follow-up to evaluate the incidence of systemic inflamma-
tory response in metastatic tumors dependent on the tumor
histology and to determine the intensity of the inflamma-
tory response as well as the time of inflammation response
in relation to objective tumor response.
As part of an exploratory retrospective analysis, PFS and
OS were evaluated separately for two groups of patients:
(1) CRP responder: Patients with normal range CRP levels
throughout the first six weeks of treatment and patients with
elevated CRP levels, who responded with an at least 30%
decrease within the first six weeks of treatment (two
consecutive measurements at least 14 days apart). (2)
CRP non-responder: Patients with ≤30% decline or increas-
ing CRP levels in two consecutive measurements 14 days
apart within the first six weeks of treatment.
Patients receiving a lead-in phase with anti-inflammatory
therapy were monitored for CRP at study inclusion and in a
14 day interval.
Metastatic Sites
On the background of the discussion, whether combined
biomodulatory therapies have any tissue specificity, i.e. are
dependent on the cellular tumor-stroma composition at an
organ site, we analyzed the response dependent on the
localization of the metastatic organ sites. To assess whether
an anti-inflammatory/angiostatic treatment approach has
any impact on the metastatic spread during progression, we
analyzed the metastatic sites after progression on study
medication.
Statistics and Data Analysis
Primary endpoints in all trials were PFS and treatment
safety. Analysis of treatment safety was restricted to
patients receiving study medication, analysis of the tumor
response to patients who were treated for at least three
weeks. The overall response rate was defined as percentage
of patients with confirmed CR or PR. SD was defined as no
tumor progression (<25%) during a six months treatment
interval. Response duration was calculated from randomi-
zation or study inclusion to the date of first observation of
progressive disease (PD) or death. Progression-free survival
was defined as the interval between the beginning of
treatment and disease progression. Survival duration was
calculated from randomization or study inclusion. Survival
distributions were generated using the Kaplan–Meier
162 A. Reichle, T. Vogtmethod. Survival analyses were performed on eligible
patients, the full analysis set (FAS) and on the intent-to
treat (ITT) population (defined as all randomly assigned
patients). In addition, the Fisher exact test and the “Student
t”-test were used to identify significant associations
between clinical and biologic variables.
Results
In total, 224 patients with metastatic cancer from eleven
centers and various medical specialties including urology,
dermatology, gastroenterology, and hematology/oncology
were treated within seven trials: The intention was to show
the efficacy and tolerability of a combined anti-inflammatory
(pioglitazone plus coxib) and angiostatic therapy (trofosfa-
mide or capecitabine) in advanced tumor stage and in a high
number of refractory cancer (10 to 63%). More detailed
patient characteristics may be found in the respective
publications [8–15].
All trials were initiated as palliative therapies. Therefore,
it is remarkable that we could observe objective response (3
to 48%) and continuous complete remissions independent
of the tumor type (vascular sarcoma, RCCC, melanoma,
hormone-refractory prostate cancer, cholangiocellular car-
cinoma, and Langerhans’ cell histiocytosis) in all treatment
groups (except RCCC I) (Table 2).
Median progression-free survival as the primary endpoint in
all trials is listed in Table 3. Interestingly, despite of the
inclusion of systemically pre-treated patients at a high
percentage (10–63%), the PFS rate is comparable to the
respective rate achieved in first-line therapy (trial RCC II,
Melanoma II, and cholangiocellular carcinoma). In metastatic
melanoma (Melanoma II), metronomic low-dose chemother-
apy with trofosfamide seems to be even equivalent to standard
DTIC treatment in a historical comparison [26–28].
Tailored Modeling of Tumor-associated Disease Traits
Overall, five different tumor-associated disease traits were
followed within each trial with biomodulation-derived
biomarkers: (1) Changes in the ECOG status, in (2) serum
CRP levels, (3) the resolution of paraneoplastic syndromes,
(4) objective tumor response at single metastatic organ
sites, and (5) the dissemination of metastatic disease at
tumor progression (metastatic spread).
ECOG performance status ECOG performance status
could be improved in all trials (19 to 100%). As expected
in the Melanoma II trial, no ECOG improvement was
observed within treatment arm A (without anti-inflammatory
therapy) (Table 4). An improvement of the performance
status due to inflammation control was possible on the basis
of a very low rate of grade III toxicities in all trials (Table 5).
Paraneoplastic syndromes The anti-inflammatory activity
of the chosen treatment schedules was additionally shown
by the resolution of paraneoplastic syndromes: Hypoglyce-
mia and lupus erythematodes respectively [29, 30].
Serum CRP level in follow-up The incidence of elevated
CRP levels (>10 mg/L) at study inclusion differed
considerably between the different tumor types (Table 4).
In groups with consistently elevated CRP levels (RCCC,
melanoma, sarcoma, Langerhans’ cell histiocytosis), a
significant CRP response (>30%) was observed during the
lead-in phase with anti-inflammatory therapy alone or
during 4 to 6 weeks of combined treatment. Thus, efficacy
of an anti-inflammatory therapy could be sufficiently
followed in metastatic diseases with constitutive systemic
inflammatory response (Table 4).
A CRP response indicated stable disease or objective
response in most patients; however, few patients experi-
Table 2 Combined targeting
of angiogenesis and inflamma-
tion: efficacy
Tumor type Response





Sarcomas I 21 19 16 5
Angiosarcomas 6 17 33 17
Melanoma I 19 10 5 0
Melanoma II Arm B 35 9 3 3
Langerhans’ cell histiocytosis 2 – 100 100
Renal clear cell carcinoma I
(no IFN-a)
18 0 0 0
Renal clear cell carinoma II
(plus IFN-a)
33 35 13 6
Hormone-refractory prostate cancer 36 28 6 6
Cholangiocellular carcinoma 21 24 5 5
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Therefore, CRP response indicates a tailored modeling of a
tumor-associated disease trait but CRP assessment should
not be used as a tumor marker. In HRPC, a CRP decrease
was always paralleled by PSA response, whereas CRP
response and/or ECOG improvement preceded objective
responses by months (3.1 months to 8.6 months) in all other
trials with the exception of individual patients with vascular
sarcomas [8]. Due to the observed objective tumor
responses to anti-inflammatory therapy in diseases without
initial systemic inflammatory reaction such as HRPC,
localized inflammatory tumor-associated processes have to
be suggested as basis for the observed objective tumor
responses [31].
Impact of anti-inflammatory therapy The efficacy of an
anti-inflammatory therapy alone has already been shown in
a randomized comparison in advanced cancer [32]. We can
now extend the experiences on anti-inflammatory therapy:
(1) Anti-inflammatory therapy adds further benefits to
angiostatic low-dose chemotherapy by a significant im-
provement of OS in metastatic melanoma, although the
objective response rates in both treatment arms did not
significantly differ (randomized melanoma phase II trial,
Melanoma II), and (2) the intensity of an anti-inflammatory
approach, as indicated by the extent of CRP decrease in
serum, may have significant impact on outcome (sequen-
tially performed RCC trials I/II).
Intensification of anti-inflammatory therapy Two kinds of
intensification of anti-inflammation were tested including a
second transcriptional modulator, i.e. dexamethasone
(HRPC) or interferon-alpha (RCCC II) (Table 1). The
addition of low dose interferon-alpha to pioglitazone and
COX-2 inhibitor dramatically increased the control of
tumor-associated inflammation and consecutively improved
Table 3 Progression-free/overall survival with combined angiostatic plus anti-inflammatory therapy
Trial Treatment Median Progression-free/overall survival (months)
Angiostatic Anti-inflammatory % pretreated patients Trial Historical control (first- line)
RCCC I Capecitabine Pio/Rofe 39 4.7/16.2
RCCC II Capecitabine Pio/Eto/IFN-α 21 11.5/25.6 11.0/n.a.(for sunitinib)
HRPC Capecitabine Pio/Eto/Dexa 39 3.6/14.4 n. a./17.5 (for taxotere)
Melanoma II
Arm A Trofosfamide – 63 1.2/8.2 n.a./5.6 (for DTIC)
Arm B Trofosfamide Pio/Rofe 60 2.0/18.8
Cholangiocellular carcinoma Capecitabine Pio/Rofe 10 2.0/8.0 PR plus stable disease 20–73%
Pio pioglitazone, Rofe rofecoxib, Eto etoricoxib, RCCC renal clear cell carcinoma, HRPC hormone refractory prostate cancer, n.a. not available
Table 4 Tumor-associated inflammation in metastatic cancer







response during 2 to






RenaI clear cell carcinoma I 72 69 p=0.32 22 Significant improvement
of PFS and OS in RCCC II
(non randomized)
Renal clear cell carcinoma II 100 100 p=0.0005 24
Hormone-refractory prostate cancer* 28 11 p=0.67 30
Melanoma I 81 88 p=0.004 19
Melanoma II
Arm A 87 6 p=0.52 0 Significant improvement
of overall survival
(CRP responder)
Arm B (randomized) 100 69 p=0.0007 27
Sarcoma 79 74 p=0.006 28
Angiosarcoma * 100 100 ––
Langerhans’ cell histiocytosis 100 100 – 100
*Resolution of paraneoplastic syndromes: lupus erythematodes, hypoglycaemia
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comparison). These results demonstrate that strong inflam-
mation control may be an important prerequisite for the
response in metastatic, non-resectable RCCC. In HRPC,
dexamethasone showed very modest anti-tumor activity.
However, the addition of a glitazone (plus coxib) resulted in
a high response rate, interestingly even up to the achieve-
ment of complete remission. Due to the poor monoactivity
of capecitabine in HRPC, most activity of the schedule
might be related to the anti-inflammatory approach.
Combined transcriptional modulation The combined use of
transcription modulators for inflammation control in HRPC
(dexamethasone, pioglitazone, and coxib) and in RCCC II
(interferon-alpha, pioglitazone, and coxib) – and glitazones
plus coxib in all the other tumor types – seems to improve
outcome in comparison to historical controls or is at least
equivalent but with less therapy-related toxicity. Except for
the monoactivity of metronomic low-dose chemotherapy in
advanced melanoma and presumably in angiosarcomas, all
other treatment components, i.e. interferon-alpha at very
low dose-levels, pioglitazone, coxibs, and low-dose dexa-
methasone have very modest or none mono-activity at all in
the respective tumor types [33–38]. Exclusively their
combination paves the way for objective responses via
transcriptional cross-talks.
Angiostatic therapy Metronomic low-dose chemotherapy
showed a significant activity in the randomized melanoma
trial (melanoma II) (Table 2). Recently published data
disclosed that the second drug capecitabine has a rather
modest activity in HRPC [33] when administered in a
nearly metronomic manner. Thus, most clinical effects in
HRPC may be related to a combined anti-inflammatory
activity. This observation is supported by unpublished data
indicating objective responses after a change to metronomic
low-dose treosulfan (250 mg twice daily) in patients with
progressive HRPC on study medication. In cholangiocel-
lular carcinoma, anti-inflammatory and angiostatic effects
cannot be separated and assessed in correlation to historical
data.
Metastatic sites and response To evaluate tumor-stroma-
specific activities of the administered drugs, we studied
whether specific single metastatic organ sites respond
predominantly to combined biomodulatory therapy. An
organ-specificity of combined anti-inflammatory and angio-
static activity could be observed in HRPC: in bone lesions,
resolution or >50 regression (scintigraphy) of metastatic
lesions could be observed, whereas only minor responses or
stable diseases were diagnosed in all other metastatically
involved organs.
Metastatic sites at progression Overall, 76% of the patients
within the Melanoma trial II, RCCC trial II, and HRPC trial
were systematically studied for metastatic sites at tumor
progression. Interestingly, 67% of these patients had no
additional metastatic organ sites at the time of progression,
but local tumor progression or additional metastasis in the
organ involved originally. This finding could indicate an
attenuation of metastatic spread by the combined anti-
inflammatory and angiostatic approach. Probably because
of the short median progression-free survival in Melanoma
II, no significant differences could be found between the two
treatment arms concerning metastatic spread at progression.
The treatment and response characteristics support bio-
modulatorymechanismsofaction:(1)Noorpoorsingleagent
activity of each administered drug, (2) a very moderate
toxicity profile during long-term drug administration up to
26months,(3)verydelayedobjectiveresponses,(4)improved
overall survival without an increase of response rate (ran-
domized Melanoma trial), (5) significant modulation of
tumor-associated disease traits, e.g. inflammation, ECOG
status, paraneoplastic syndromes, (6) activity depending on
the metastaticorgan siteinHRPC, and (7) predominant siteof
progression at the original localization of the metastases.
Safety Profile
The toxicity profiles of the presented biomodulatory
approaches are modest as reflected in a low rate of WHO
grade >2 toxicities and no grade 4 toxicities (Table 6).
Thus, the desirable therapeutic effects could be achieved by
Table 5 Toxicities WHO Grade 3 (no Grade 4 toxicities) within all seven trials (n=224 patients)
Toxicity No. of patients (%) Trial Toxicity related to the following drug
Cushing syndrome 1 (0.4) HRPC Dexamethasone
Depression 1 (0.4) RCCC Interferon-alpha
Hand-Foot-Syndrome 5 (2.2) CCC, HRPC Capecitabine
Hematotoxicity 14 (6.2) All trials Metronomic chemotherapy
Edema 5 (2.2) All trials COX-2 inhibitor
Nausea/Vomiting 3 (1.3) All trials –
CCC=cholangiocellular carcinoma, RCCC=renal clear cell carcinoma, HRPC=hormone refractory prostate cancer
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status before objective tumor response will be achieved.
Because of the low rate of grade 3 toxicities, long-term
drug administration up to more than two years was possible
(median time on study medication 3.6 months (range 0.5 to
26.0). The low rate of toxicities > grade 2 might be related
to the fact that each drug is not administered at a maximal
tolerable dose, even not at a dose level where mono-activity
may be observed.
A second important point for safety evaluation is the
question whether activating biomodulators may promote
tumor activity. The stimulatory therapy with transcriptional
modulators (interferon-alpha, PPAR-alpha/gamma agonist,
dexamethasone) did obviously not enhance the percentage
of patients with continuously progressive disease compared
to standard therapies in the individual tumor types.
Discussion
The uniform treatment schedules presented were initially
chosen to facilitate disease stabilization in patients with
advanced and pre-treated cancer with less toxic agents.
Surprisingly, it turned out that these treatment schedules
have the capacity to induce objective responses (3 to 48%)
and, in individual patients, even continuous complete
remissions in every tumor type mentioned. Furthermore,
they may induce OS rates, which compare with established
standard first-line therapies.
With respect to the multi-facetted activities of the
administered drugs (anti-proliferative, angiostatic, anti-
inflammatory, metabolic activity, immunomodulatory), and
their differential cell-specific activities, the exact mecha-
nisms of action of the selected drug combinations are
difficult to pin down [17, 18, 39]. The studied drug
combinations are interacting with the systems biology of
the different cell types at regulatory sites and have both
genomic and non-genomic activity.
With the exception of individual patients suffering from
vascular sarcoma, responses to therapy occurred very
delayed and three phases were observed: (1) Inhibition
of further tumor progression, (2) prolonged disease stabi-
lization by 3.1 months to a mean of 8.6 months, followed
by (3) objective responses. In some tumor types, response
to therapy could be monitored by a serum parameter, C-
reactive protein, indicating the tailored modeling of a
tumor-associated disease trait, namely inflammation. Sys-
temic tumor-associated inflammation, however, was no
prerequisite for objective tumor response to a combined
anti-inflammatory therapy approach as shown in hormone
refractory prostate cancer that has a very low incidence of
systemic inflammatory events [31].
On the basis of these observations, we now postulate
tumor-associated inflammation as both a pathophysiolog-
ically important element and a therapeutic target but
without presupposing causal relationships between inflam-
mation and tumor progression. On the contrary, the
prerequisites for our clinical observations, i.e. the multi-
facetted regulatory activities of the single administered
drugs and the differential responses of the multiple cell
types within the tumor compartment, reveal the relations of
conditioned and conditioning tumor-promoting moments as
reciprocal on the basis of pathophysiologically important
interacting elements (e.g. inflammation, angiogenesis, and
tumor cell proliferation). The still ‘indistinct’ but regulatory
activity profile of the administered drugs and the favorable
therapy results of the uniform treatment concept in a broad
variety of different tumor types strongly support our
hypothesis that tumor growth may be successfully attenu-
ated by targeting the tumor system’s biology simultaneous-
ly at multiple regulatory sites, e.g. (nuclear) transcription
factors.
Pathologic systems biological processes in cancer may
be reported from different observation levels: (1) In
Loewenstein’s view pathologic cancer processes are pre-
dominantly mirrored in a deficient cell–cell communication
Table 6 Combined targeting of angiogenesis and inflammation: patients with progressive disease
Tumor type No. of patients Targeted (nuclear) transcription factors Progressive disease No. of patients (%)
Sarcomas I 21 PPAR α/γ,P P A Rδ 4 (19)
Angiosarcoma 6 PPAR α/γ,P P A Rδ 0
Melanoma I 19 PPAR α/γ,P P A Rδ 4 (21)
Melanoma II Arm B 35 PPAR α/γ,P P A Rδ 6 (17)
Langerhans’ cell histiocytosis 2 PPAR α/γ,P P A Rδ 0
Renal clear cell carcinoma I 18 PPAR α/γ,P P A Rδ 9 (50)
Renal clear cell carcinoma II 33 PPAR α/γ PPAR δ via IFN-α receptor 2 (7)
Hormone-refractory prostate cancer 36 PPAR α/γ,P P A Rδ glucocorticoid receptor 5 (14)
Cholangiocellular carcinoma 21 PPAR α/γ,P P A Rδ 0
Receptor ligands: PPAR α/γ agonist, PPARδ antagonist (COX-2 inhibitor), dexamethasone, interferon-alpha
PPAR peroxisome proliferator-activated receptor
166 A. Reichle, T. Vogt[40]. (2) The initial source of observation may also be an
altered systems-associated cell composition, and (3) dis-
torted functions of single cell systems within the tumor
microenvironment [1, 3, 6]. Inflammatory processes have
been identified to be involved in tumor systems biology
independently of the viewpoint of observation.
One aspect is getting of growing systems-therapeutic
interest since normal adult and cancer stem cells may be
detected by selective expression of the transcription factor Okt-
4[ 41, 42]: Inflammation plays a critical role on all virtual
stages of tumor development, tumor initiation, promotion and
progression [43]. The inhibition of gap junctional communi-
cation has been identified as an important mechanism by
which inflammatory processes affect cancer development:
Cancer cells exist in two forms, those that do not express
connexin (gap junction genes), and those that express
connexin genes but that gap junction function has been
rendered non-functional by oncogenes/loss of tumor suppres-
sor genes [44]. Here the use of agents to turn on critical genes,
i.e., such as the connexin genes seems to be important [45–
47]. That the cancer stem cell must be promoted by a number
of inflammatory conditions, particularly in the metastatic
stage of cancer disease (cachexia!) fits with the successful use
of anti-inflammatory therapy components in the present
systems-targeted treatment strategy [48].
Conventional therapy methods commonly neglect the
complexity of the tumor compartment. They mainly target
the molecular-genetically highly variable tumor cell, whose
variability is explained by the complexity of the tumor
development. By blocking a pathological signaling pathway
with a small molecule or an antibody, the whole tumor
system should be destroyed, synonymously with the as-
sumption that tumor development could result from a single
causative principle. Furthermore, combining cytotoxic ther-
apy elements guided by the simple availability of drugs buys
moderately enhanced efficacy at a simultaneously enhanced
toxicity profile, as shown by many studies.
A lead back to a final first principle that may be
therapeutically targeted to eradicate metastatic cancer is
generally not permitted, in particular in knowledge of the
multi-facetted activity profile of the administered biomo-
dulatory agents. However, instead of such a lead back to a
first principle, we have to deal with multiple and various
constellations of elements (aggregated action effects), one
of which – in our case – is tumor-associated inflammation.
The constellation of elements has to be broken down to its
single moments, but, simultaneously, we have to under-
stand the relationship between one another rather than
separately adding one to another and thereby neglecting the
importance within the complex constellation. The principle
therapeutic difficulty lies in this point.
The therapeutic components chosen directly address this
difficulty based on the hypothesis that the combined
activity of regulatory but pleiotropic agents, particularly
transcription modulators (besides the angiostatic approach),
may shape the tumor’s organization, e.g. the ‘wound
healing’ mechanisms, by attenuating simultaneously multi-
ple activities involved in tumor growth such as angiogen-
esis, anti-inflammation, and proliferation. This hypothesis
is supported by seven treatment-related characteristics: (1)
No or poor single agent activity of each administered drug
(predominantly combined regulatory activity) when given
alone, (2) a very moderate toxicity profile during long-term
drug administration (presumably no dose-response relation-
ship), (3) very delayed objective responses (stable shaping
and focusing of the tumor system’s organization), (4)
improved overall survival without an increase of the
response rate in arm B of the randomized Melanoma II
trial (biomodulatory activity), (5) significant modulation of
tumor-associated disease traits, e.g. inflammation, ECOG
status, paraneoplastic syndromes (biomodulation-derived
biomarkers), (6) activity depending on the metastatic organ
site in HRPC (tumor-stroma-specificity as expected from
the known differential behavior of the various cell types
within the tumor compartment, and the varying stroma cell
compositions at the different metastatic sites), and (7)
predominant site of progression at the original localization
of the metastases (hints for impact on metastatic processes).
Preclinical data on the action of COX-2 inhibitors and
PPAR-alpha agonists are already revealing antimetastatic
activity [49, 50].
Even if metronomic chemotherapy has any cytotoxic
activity in the classic sense, the response characteristics do
not support a response behavior as usually found in
response to pulsed chemotherapy.
Systems-directed therapy: Communicationdesign betweentumor
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Enhanced complexity:
Multiple action effects
Fig. 1 The differential response patterns within our clinical trials
indicate the therapies’ systems biological activity. Understanding
systems biology as adjustable size may break through the barrier of
complex tumor–stroma-interactions in a therapeutically relevant way:
Comparatively high efficacy at moderate toxicity. Structured systems-
directed therapies in metastatic cancer may get a source for detecting
tumor-associated complex aggregated action effects as adjustable sizes
available for targeted biomodulatory therapies
Systems biology: a therapeutic target for tumor therapy 167The clinical efficacy of the combined anti-inflammatory
and angiostatic approach in different tumor types reveals
preserved regulatory elements for targeting ‘wound healing’
processes with transcriptional regulators (biomodulatory
agents) in tumor and adjacent stroma cells. (1) The
favorable clinical results achieved with a small repertoire
of transcriptional modulators indicate a constitutive dysre-
gulation of distinct transcription factors, which – on the
other hand – seems to be paradoxically linked to the
heterogeneous tumor-associated molecular-genetic aberra-
tions depending on the tumor type [51]. (2) The combined
genomic/non-genomic therapy approach specifically shapes
the organization of the tumor–stroma-interaction. (3) The
clinically combined activity of (nuclear) transcription
factors in the RCCC II and HRPC trial give sufficient
clinical evidence for a crosstalk between drug-activated/
deactivated transcription factors.
The focus on the systems biology of a tumor as the
original target of cancer therapy necessitates biomarkers
that indicate stable response in the field of tumor-associated
disease traits or tumor-associated phenomena such as
inflammation, angiogenesis, coagulation, and metabolism.
Rather than the primary or “classic” markers for tumor
response including tumor shrinkage or decrease of tumor
markers, this new group of markers reflects efficacious
biomodulation. However, we are aware of the limitation
that some of these tumor-associated phenomena mirroring
tumor biomodulation are sometimes difficult to follow on a
systemic level. They can not be uniformly interpreted
across tumor entities as demonstrated in our example of
HRPC in comparison to other tumors, when inflammation
seems to be quite differently integrated in the tumors’
pathophysiology: PSA decline was paralleled but not
preceded by a CRP decline in HRPC, whereas in other
tumor types including RCCC decrease of CRP or ECOG
performance improvement preceded tumor response.
In the immediate presence and future, biomodulatory
therapy approaches of metastatic tumors could be method-
ological tools of individualized tumor therapy: In contrast
to ‘causal’ therapy approaches aiming at blocking aberrant
tumor-associated pathways by a restricted repertoire of
highly specific drugs, multiple potential modulators (acti-
vators and deactivators) of transcriptional processes are
available for biomodulatory therapy approaches. According
to our experiences, mono-activity of a single transcription
modulator is no prerequisite for its successful use and their
combined administration activity could be followed by
respective biomarkers. Close monitoring would further
allow us to choose other modulator combinations in cases
of weak interactivity to facilitate objective tumor response.
Finally, the constitutive dysregulation of transcriptional
activity is shown to be an important target for biomodula-
tory therapy approaches in metastatic cancer. Biomodula-
tion in metastatic tumors provides tools for recognizing
patterns in therapy-associated events via biomodulation-
derived biomarkers. Thereby, it enables (1) the shaping of
the tumor system’s organization and (2) the uncovering of
endogenous sources such as transcription factors and their
crosstalks for managing growth behavior by counterbalanc-
ing the tumor systems’ biology.
Our seven published phase II trials on combined targeted
therapy of tumor-associated wound healing mechanisms,
e.g. inflammation and neoangiogenesis, have shown that
using an approach for understanding systems biology as
adjustable size, we may break through the barrier of
complexity of tumor-stroma-interactions in a therapeutical-
ly relevant way (Fig. 1). For a targeted modulation,
elements such as inflammation and neoangiogenesis are
available, which are dysregulated on the basis of acquired
chromosomal aberrations. Biomodulation of systems bio-
logical processes facilitate comparatively high efficacy at
moderate toxicity.
General interpretations of the tumor’s systems biology
may not be performed in context-free explanations. The
requirements of application (therapy schedule, tumor type)
and the number of surrogate markers define the way the
interpretation is conducted. Additionally, they define the
hermeneutic understanding of extremely complex cellular
interactions correspondingly to the chosen picture, the
wound healing mechanisms. In the present case, this means
the following: Naturally, the administered drugs, particu-
larly the transcriptionally active modulators, have still an
insufficiently illuminated spectrum of activities, which may
be even dependent on the cell type. General interpretations
concerning the systems biology do not obey the same
categories of refutation as general theories and remain per
se open for discussion. The logic of an explanation of the
tumor’s systems biology is the result of a connection
between a hermeneutic understanding (wound healing
mechanisms) and the causal explanation (e.g. co-regulatory
activity of transcription factors).
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